Research progress of metformin in non-Hodgkin lymphoma

doi:10.3760/cma.j.cn371439-20220414-00083

Abstract

Abstract:

Preclinical studies have shown that metformin, an activator of AMP-activated protein kinase （AMPK）, can inhibit the growth of lymphoma cells without affecting the function of normal lymphocytes, promote the apoptosis of lymphoma cells and improve the tumor immune environment. Clinical studies have shown that metformin can improve the efficacy of chemotherapy and prognosis of non-Hodgkin lymphoma （NHL）. Through the influence on glucose metabolism, it can improve blood glucose level and reduce the incidence of steroid diabetes. The main molecular mechanisms of metformin against NHL include activating AMPK in tumor cells, inhibiting mammalian target of rapamycin signal, inhibiting key cholesterol synthesis, improving glucose metabolism, enhancing highly cytotoxic T lymphocyte （CTL） activity and so on. Current research shows that metformin may become a new strategy for the treatment of NHL.

Key words: Metformin, Lymphoma, non-Hodgkin, Glucocorticoids, AMP-activated protein kinase

Wang Liuxue, Xi Xiaoping, Liu Jingjing, Shen Guomin, Yang Haiping. Research progress of metformin in non-Hodgkin lymphoma[J]. Journal of International Oncology, 2022, 49(7): 436-440.

References 31

[1]	中国抗癌协会淋巴瘤专业委员会, 中国医师协会肿瘤医师分会, 中国医疗保健国际交流促进会肿瘤内科分会. 中国淋巴瘤治疗指南(2021年版)[J]. 中华肿瘤杂志, 2021, 43(7): 707-735. DOI: 10.3760/cma.j.cn112152-20210516-00382. doi: 10.3760/cma.j.cn112152-20210516-00382
[2]	Chiba S, Sakata-Yanagimoto M. Advances in understanding of angioimmunoblastic T-cell lymphoma[J]. Leukemia, 2020, 34(10): 2592-2606. DOI: 10.1038/s41375-020-0990-y. doi: 10.1038/s41375-020-0990-y
[3]	赵可, 王华庆. 复发/难治外周T细胞淋巴瘤的新药治疗进展[J]. 国际肿瘤学杂志, 2020, 47(6): 321-326. DOI: 10.3760/cma.j.cn371439-20200507-00029. doi: 10.3760/cma.j.cn371439-20200507-00029
[4]	龚予希, 翟博雅, 杨野梵, 等. 弥漫大B细胞淋巴瘤分型及预后研究进展[J]. 白血病·淋巴瘤, 2021, 30(9): 565-568. DOI: 10.3760/cma.j.cn115356-20210118-00019. doi: 10.3760/cma.j.cn115356-20210118-00019
[5]	Cunha Júnior AD, Pericole FV, Carvalheira JBC. Metformin and blood cancers[J]. Clinics (Sao Paulo), 2018, 73(suppl 1): e412 s. DOI: 10.6061/clinics/2018/e412s. doi: 10.6061/clinics/2018/e412s
[6]	Biondani G, Peyron JF. Metformin, an anti-diabetic drug to target leukemia[J]. Front Endocrinol (Lausanne), 2018, 9: 446. DOI: 10.3389/fendo.2018.00446. doi: 10.3389/fendo.2018.00446
[7]	Wang Y, Xu W, Yan Z, et al. Metformin induces autophagy and G₀/G₁ phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways[J]. J Exp Clin Cancer Res, 2018, 37(1): 63-75. DOI: 10.1186/s13046-018-0731-5. doi: 10.1186/s13046-018-0731-5
[8]	Chukkapalli V, Gordon LI, Venugopal P, et al. Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells[J]. Oncotarget, 2018, 9(30): 21166-21181. DOI: 10.18632/oncotarget.24989. doi: 10.18632/oncotarget.24989
[9]	Kaneto H, Kimura T, Obata A, et al. Multifaceted mechanisms of action of metformin which have been unraveled one after another in the long history[J]. Int J Mol Sci, 2021, 22(5): 2596-2609. DOI: 10.3390/ijms22052596. doi: 10.3390/ijms22052596
[10]	Li M, Li X, Zhang H, et al. Molecular mechanisms of metformin for diabetes and cancer treatment[J]. Front Physiol, 2018, 9: 1039. DOI: 10.3389/fphys.2018.01039. doi: 10.3389/fphys.2018.01039
[11]	Shi WY, Xiao D, Wang L, et al. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy[J]. Cell Death Dis, 2012, 3(3): e275. DOI: 10.1038/cddis.2012.13. doi: 10.1038/cddis.2012.13
[12]	Jiang XN, Zhang Y, Wang WG, et al. Alteration of cholesterol metabolism by metformin is associated with improved outcome in type Ⅱ diabetic patients with diffuse large B-cell lymphoma[J]. Front Oncol, 2021, 11: 608238. DOI: 10.3389/fonc.2021.608238. doi: 10.3389/fonc.2021.608238
[13]	Bagaloni I, Visani A, Biagiotti S, et al. Metabolic switch and cytotoxic effect of metformin on Burkitt lymphoma[J]. Front Oncol, 2021, 11: 661102. DOI: 10.3389/fonc.2021.661102. doi: 10.3389/fonc.2021.661102
[14]	Meng X, Lu Z, Lv Q, et al. Tumor metabolism destruction via metformin-based glycolysis inhibition and glucose oxidase-mediated glucose deprivation for enhanced cancer therapy[J]. Acta Biomater, 2022, 145: 222-234. DOI: 10.1016/j.actbio.2022.04.022. doi: 10.1016/j.actbio.2022.04.022
[15]	Eikawa S, Nishida M, Mizukami S, et al. Immune-mediated antitumor effect by type 2 diabetes drug, metformin[J]. Proc Natl Acad Sci U S A, 2015, 112(6): 1809-1814. DOI: 10.1073/pnas.1417636112. doi: 10.1073/pnas.1417636112
[16]	Cha JH, Yang WH, Xia W, et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1[J]. Mol Cell, 2018, 71(4): 606-620.e7. DOI: 10.1016/j.molcel.2018.07.030. doi: 10.1016/j.molcel.2018.07.030
[17]	Bahrambeigi S, Shafiei-Irannejad V. Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin[J]. Biochem Pharmacol, 2020, 174: 113787. DOI: 10.1016/j.bcp.2019.113787. doi: 10.1016/j.bcp.2019.113787
[18]	Zhang Z, Li F, Tian Y, et al. Metformin enhances the antitumor activity of CD8⁺ T lymphocytes via the AMPK-miR-107-Eomes-PD-1 pathway[J]. J Immunol, 2020, 204(9): 2575-2588. DOI: 10.4049/jimmunol.1901213. doi: 10.4049/jimmunol.1901213 pmid: 32221038
[19]	Gonzalez-Gonzalez JG, Mireles-Zavala LG, Rodriguez-Gutierrez R, et al. Hyperglycemia related to high-dose glucocorticoid use in noncritically ill patients[J]. Diabetol Metab Syndr, 2013, 5: 18. DOI: 10.1186/1758-5996-5-18. doi: 10.1186/1758-5996-5-18 pmid: 23557386
[20]	Lamar ZS, Dothard A, Kennedy L, et al. Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration—a retrospective study[J]. Leuk Lymphoma, 2018, 59(8): 1871-1877. DOI: 10.1080/10428194.2017.1410889. doi: 10.1080/10428194.2017.1410889
[21]	胡洋, 许艳洁, 李梦真, 等. 合并糖尿病及治疗过程中血糖升高对弥漫大B细胞淋巴瘤患者预后的影响[J]. 中华血液学杂志, 2021, 42(2): 151-157. DOI: 10.3760/cma.j.issn.0253-2727.2021.02.011. doi: 10.3760/cma.j.issn.0253-2727.2021.02.011
[22]	Drozd-Sokolowska J, Zaucha JM, Biecek P, et al. Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP—the PLRG report[J]. Sci Rep, 2020, 10(1): 3517. DOI: 10.1038/s41598-020-60565-7. doi: 10.1038/s41598-020-60565-7 pmid: 32103128
[23]	Landis D, Sutter A, Fernandez F, et al. The effect of metformin on glucose metabolism in patients receiving glucocorticoids[J]. Am J Med Sci, 2022: S0002- 9629(22)00208-7. DOI: 10.1016/j.amjms.2022.04.027. doi: 10.1016/j.amjms.2022.04.027
[24]	Ochola LA, Nyamu DG, Guantai EM, et al. Metformin’s effectiveness in preventing prednisone-induced hyperglycemia in hematological cancers[J]. J Oncol Pharm Pract, 2020, 26(4): 823-834. DOI: 10.1177/1078155219873048. doi: 10.1177/1078155219873048 pmid: 31495292
[25]	Singh AR, Gu JJ, Zhang Q, et al. Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma[J]. Cancer Metab, 2020, 8: 10. DOI: 10.1186/s40170-020-00213-w. PMID: 32647571. doi: 10.1186/s40170-020-00213-w pmid: 32647571
[26]	Fan X, Zhong HJ, Zhao BB, et al. Metformin prolonged the survival of diffuse large B-cell lymphoma and grade 3b follicular lymphoma patients responding to first-line treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone: a prospective phase Ⅱ clinical trial[J]. Transl Cancer Res, 2018, 7(4): 1044-1053. DOI: 10.21037/tcr.2018.07.20. doi: 10.21037/tcr.2018.07.20
[27]	Wang Y, Maurer MJ, Larson MC, et al. Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma[J]. Br J Haematol, 2019, 186(6): 820-828. DOI: 10.1111/bjh.15997. doi: 10.1111/bjh.15997
[28]	Chen K, Li Y, Guo Z, et al. Metformin: current clinical applications in nondiabetic patients with cancer[J]. Aging (Albany NY), 2020, 12(4): 3993-4009. DOI: 10.18632/aging.102787. doi: 10.18632/aging.102787
[29]	Trucco M, Barredo JC, Goldberg J, et al. A phase Ⅰ window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin[J]. Pediatr Blood Cancer, 2018, 65(9): e27224. DOI: 10.1002/pbc.27224. doi: 10.1002/pbc.27224
[30]	Singh SV, Chaube B, Mayengbam SS, et al. Metformin induced lactic acidosis impaired response of cancer cells towards paclitaxel and doxorubicin: Role of monocarboxylate transporter[J]. Biochim Biophys Acta Mol Basis Dis, 2021, 1867(3): 166011. DOI: 10.1016/j.bbadis.2020.166011. doi: 10.1016/j.bbadis.2020.166011
[31]	Laporte F, Hamdi S, Oksman F, et al. Auto-immune neutropenia associated with metformin in a patient with splenic marginal zone lymphoma[J]. Pharm World Sci, 2008, 30(4): 319-321. DOI: 10.1007/s11096-008-9218-3. doi: 10.1007/s11096-008-9218-3 pmid: 18392686